Braden Parker
Corporate Officer/Principal bij ORCHARD THERAPEUTICS PLC
Profiel
Braden Parker is currently the Chief Commercial Officer at Orchard Therapeutics Plc.
Previously, he worked as the Vice President & General Manager at PTC Therapeutics, Inc. He completed his undergraduate degree at the University of Notre Dame and holds an MBA from The Leonard N Stern School of Business.
Actieve functies van Braden Parker
| Bedrijven | Functie | Begin |
|---|---|---|
| ORCHARD THERAPEUTICS PLC | Corporate Officer/Principal | - |
Eerdere bekende functies van Braden Parker
| Bedrijven | Functie | Einde |
|---|---|---|
| PTC THERAPEUTICS, INC. | Corporate Officer/Principal | - |
Opleiding van Braden Parker
| The Leonard N Stern School of Business | Masters Business Admin |
| University of Notre Dame | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| PTC THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Orchard Therapeutics Plc
 Orchard Therapeutics Plc Pharmaceuticals: MajorHealth Technology Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom. | Health Technology |
